Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Last Updated: January 30, 2023

Amisulpride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for amisulpride and what is the scope of freedom to operate?

Amisulpride is the generic ingredient in one branded drug marketed by Acacia and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amisulpride has sixty-three patent family members in twenty-six countries.

There are four drug master file entries for amisulpride. One supplier is listed for this compound.

Summary for amisulpride
International Patents:63
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 4
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 126
Clinical Trials: 65
Patent Applications: 6,272
What excipients (inactive ingredients) are in amisulpride?amisulpride excipients list
DailyMed Link:amisulpride at DailyMed
Recent Clinical Trials for amisulpride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Premier Research Group plcPhase 2/Phase 3
Amicus CD LLCPhase 2/Phase 3
Acacia Pharma LtdPhase 2/Phase 3

See all amisulpride clinical trials

Pharmacology for amisulpride

US Patents and Regulatory Information for amisulpride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-002 Sep 1, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acacia BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-002 Sep 1, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for amisulpride

Country Patent Number Title Estimated Expiration
European Patent Office 2567690 Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par la chimiothérapie (Use of amisulpride for treating chemotherapy-induced nausea and vomiting) See Plans and Pricing
Hong Kong 1179152 氨磺必利用於製備治療噁心、嘔吐和反胃的病症的藥劑的用途 (THE USE OF AMISULPRIDE FOR PRODUCING AN AGENT IN THE THERAPY OF NAUSEA, VOMITING AND RETCHES) See Plans and Pricing
Denmark 2796171 See Plans and Pricing
Japan 2013522181 See Plans and Pricing
Japan 5886213 See Plans and Pricing
Poland 2796171 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
AstraZeneca
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.